Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 8, 2024
Daily News
April 8, 2024
- GSK Japan Shooting for 80% Goal for Paid Paternity Leave in 2024
April 8, 2024
- New LLP Coverage Scheme Intended for Generic Promotion: Payer Exec
April 8, 2024
- Otsuka, Verily Join Forces to Run Mental Health Registry
April 8, 2024
- Generic Rate Hits Record for 6th Straight Quarter in October-December: JGA
April 8, 2024
- Japan Ethical Drug Sales Zoom 12.1% in February: Crecon
April 8, 2024
- Keytruda Tops Japan Sales List for 6th Month in March: Encise
April 8, 2024
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…